Bruker (BRKR)
(Real Time Quote from BATS)
$61.65 USD
+0.44 (0.72%)
Updated Jul 10, 2024 12:20 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BRKR 61.65 +0.44(0.72%)
Will BRKR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BRKR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRKR
Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?
Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds
BRKR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab
Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Other News for BRKR
Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin
Agilent Hit By Cyclical Headwinds, But The Growth Story Remains Intact Long Term
Rags to Riches: 3 Nanotech Stocks That Could Make Early Investors Rich
Cellens Announces Collaboration with Bruker BioAFM to Advance Mechanobiology Technology for Cancer Detection
Jefferies Keeps Their Buy Rating on Bruker (BRKR)